Date: May 04, 2012 Source: Company Data (
click here to go to the source)
Summary
Digestive Care, Incorporated was founded by Tibor Sipos, a retired doctor who provided research and development for Johnson & Johnson. Sipos chose to leave Johnson & Johnson to pursue the development of unique treatments and therapies for patients with cystic fibrosis as they had deemed that developing a treatment to benefit that small of a demographic would not be a viable pursuit for a corporation of their size. Digestive Care, Inc. has become successful on a national level with the development of Pancrecarb. They have received funding from Ben Franklin Technology Partners to allow them to progress further into the research and development of cystic fibrosis treatments.
Pancrecarb is a concentrated combination of lipase, amylase and protease launched by Digestive Care, Incorporated. Pancrecarb has been approved by the FDA for patients with exocrine pancreatic enzyme insufficiency. Pancrecarb is administered in capsule form.
Eligibility
Digestive Care, Inc Assistance Program, a patient assistance program provided by Digestive Care, Incorporated, offers Pancrecarb at no cost for up to 90 days to those who are eligible for the program. Eligibility is based off of the following requirements:
- You must be a citizen of the United States or its Territories.
- You must not be covered by private or public health insurance.
- You must meet an undisclosed income guideline.
The medication must be sent to the physicians office.
Patients with a very high co-pay should still apply.
